Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.35p -10.94% 2.85p 728,827 14:15:40
Bid Price Offer Price High Price Low Price Open Price
2.80p 3.14p 3.49p 2.85p 3.40p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 15.00

Vernalis (VER) Latest News (2)

More Vernalis News
Vernalis Takeover Rumours

Vernalis (VER) Share Charts

1 Year Vernalis Chart

1 Year Vernalis Chart

1 Month Vernalis Chart

1 Month Vernalis Chart

Intraday Vernalis Chart

Intraday Vernalis Chart

Vernalis (VER) Discussions and Chat

Vernalis Forums and Chat

Date Time Title Posts
19/3/201814:20VERNALIS - time to buy?1,784
24/10/201018:57VERNALIS - 500p by December 2010?465
15/9/200916:32Vernalis (VER): Charts and discussion thread38
15/9/200916:31VERNALIS *** UNDERVALUED***1
15/9/200915:38Vernalis - short this junk to 40p?23

Add a New Thread

Vernalis (VER) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Vernalis trades in real-time

Vernalis (VER) Top Chat Posts

Vernalis Daily Update: Vernalis is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VER. The last closing price for Vernalis was 3.20p.
Vernalis has a 4 week average price of 2.85p and a 12 week average price of 2.85p.
The 1 year high share price is 26.25p while the 1 year low share price is currently 2.85p.
There are currently 526,437,178 shares in issue and the average daily traded volume is 2,163,804 shares. The market capitalisation of Vernalis is £15,003,459.57.
yasx: Chuckle chuckle. ------------------------- romeike23 Feb '17 - 12:13 - 1562 of 1777 I doubt there is more to fall, I expect the share price to gradually recover to same level as before the results, about 32p. The results raised more questions that answers as is so common on AIM but the company is in a decent financial position and has everything to play for still.
lcwanderer: The share price has gone from 86p to 8.6p in just over two years under the stewardship of Ian Garland. In any other line of work such an incompetent managerial record would result in the sack.
romeike: I recently reduced my holding here by over 60% as the opportunity arose to swap out the funds into Shire, with its share price severely down for no good reason it makes a lot of sense to do so - far more certainty of a recovery and profits at Shire than here. And CEO Flemming O is leagues ahead of this no hoper Ian Garland at Vernalis. Looks very much like Vernalis strategy is hostage to its partner Tris, with no control over what looks like an increasingly chaotic situation. Can only hope Vernalis is applying pressure but months on and still no word of progress. Strategy making less and less sense with ongoing cash burn at $20m but revenues just a few million, how can this ever make sense without more products hitting the market in a reasonable time.
bones698: fund raising coming judging by the lack of news and share price fall just like agl and nano . Expect it to level off jut above the issue price imo . So far looks like it could be at 8p or possibly 5p . Usual share price reaction when the company goes to the city asking for money no other real explanation I can see
romeike: Share price propped up by bottom feeders. Not going to make any significant moves until a new strategy is made clear and we get some positive news. But yes, at least this isn't PFG of subprime vehicle finance fame - chances of recovery looking slim there. More likely it will end in administration.
bountyhunter: Agreed, and this is a weird headline given that the share price has dropped 10% on today's disappointing news...
bountyhunter: interims announced... Ian Garland, Chief Executive Officer, commented, "We are encouraged with the progress we have made in the last six months as we continued to expand our sales and saw further progress in our cough cold development pipeline. "Midway through the 2016/17 cough cold season we have seen Tuzistra(R) XR prescriptions continue to grow steadily. We believe the emergence of high performing sales representatives in all regions across the US validates the market potential for Tuzistra(R) XR. We are, however, still in the early stages of the launch and our focus for the second half of the season is to drive sales-force effectiveness and so further increase the proportion of high performing sales territories. With continued prescription growth expected, the annualised run-rate at the end of June 2017 should provide a more meaningful predictor of sales performance for future years. "We expect to achieve a number of milestones from the remainder of the cough cold franchise in 2017, including potential approvals by FDA of CCP-07 and CCP-08. We also continue to seek other opportunities to leverage our US commercial infrastructure and remain very excited about the growth potential of the business." Presentation & Conference Call Vernalis management will host a presentation at 9.30am (UK) today at the offices of FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. It will also be available via webcast at hxxp:// and and via conference call, which can be joined by dialling: +44 (0) 20 3003 2666, Passcode 5780976# Please contact Jack Bower at FTI consulting +44 (0) 20 3727 1000 for details. Http://
romeike: Good results tomorrow ought to trigger a decent recovery in the share price here. I think we are looking for some evidence that that Tuzistra XR will at the very least comfortably replace revenue that would previously have come from sales of Frovatriptan. Yes, for the current year the recently announced milestone payment already more than achieves this, but Tuzistra XR will be a reliable, regular source of income that keeps growing over the long term. I'm looking forward to any further information about the H2 launches that will fully utilise the sales team into which so much investment went last year. Good luck all!
woodcutter: I've been researching a number of pharma co's where the share price has fallen considerably recently and once again I'm finding a similar pattern on director emoluments. For a business that turned over roughly £12m last year to see the directors taking out £1.7m in remuneration seems unacceptable to me. Noses in the trough comes to mind. Garland was paid £865K of which £363K was bonus related. All the bonus payments were attributed to company product milestones nothing was realted to anything financial neither was it related to share price performance. There's a total of 8 directors including the non execs for a business with £12m revenue. Woodford and Invesco need to pressure the board to show restraint. I've no doubt there's potential here but it needs to be realised before these kind of awards are given. One question that does seem obvious is what differentiates VER cold medication from the wider range of products already on the market? (I know they do more than cold remedies but these seem to be at the forefront of immediate revenue generation) It's now on my watch list but need to see greater revenue and stricter cost control otherwise there'll end up being a further placing. I await the results with anticipation. woody
bountyhunter: RNS today... "Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis. In February 2015, the Company licensed exclusive, worldwide rights to its adenosine receptor antagonist programme, CPI-444, for use in all therapeutic applications to Corvus, a US-based biotechnology company focused on developing novel immuno-oncology therapies. CPI-444 is a patented small molecule that is now being evaluated in a Phase 1/1b trial in patients with advanced cancers. It is the lead molecule in Corvus' pipeline and is being developed both as a single agent and in combination therapy. The clinical trial utilizes an adaptive design that allows expansion of disease-specific cohorts upon reaching certain pre-defined endpoints. Corvus announced positive data from its Phase 1/1b study in January 2017, having achieved the clinical study protocol criteria for expansion in the cohort of patients with renal cell carcinoma with single agent CPI-444. This study expansion triggers the first clinical milestone payment of $3 million under the licensing agreement. Corvus has stated that, if early findings are confirmed with longer follow up and a larger set of patients in this expanded study, a registration trial could commence by the end of 2017. Corvus was launched through a $33.3 million Series A fundraising in 2014 by the founder and former senior management at Pharmacyclics Inc and it raised a further $74.8 million Series B fundraising in 2015 and $70.7 million via a US IPO in March 2016. The licensing deal has the potential for Vernalis to earn approximately $220 million in milestones from all indications, subject to development, regulatory and sales milestones being achieved. In addition, there are mid-single digit royalties payable if a product reaches the market, with the potential to reach low-double digit royalties in certain circumstances..." Http://
Vernalis share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180319 14:35:56